1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Everest Medicines Limited
  6. News
  7. Summary
    1952   KYG3224E1061

EVEREST MEDICINES LIMITED

(1952)
  Report
Delayed Hong Kong Stock Exchange  -  05/19 04:08:33 am EDT
21.80 HKD   -2.90%
04/07Everest Medicines to Form Vaccine JV With China Resources Pharmaceutical
MT
04/06Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
CI
04/05Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Everest Medicines Limited Announces Taiwan FDA Has Accepts New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer

01/03/2022 | 07:01pm EDT

Everest Medicines Limited announced that Taiwan Food and Drug Administration (TFDA) has accepted the submission of a New Drug Application (NDA) for sacituzumab govitecan (SG) in adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. The treatment was granted Pediatric and Rare Severe Disease Priority Review Designation by the Taiwan FDA in July 2021. Under the trade name Trodelvy®, the U.S. FDA previously granted accelerated approval to SG in April 2020 and then expanded its indication with full approval in April 2021 for adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. In May 2021, Everest announced that the China National Medical Products Administration accepted its Biologics License Application with priority review for SG for adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. In November 2021, Everest announced topline results for its Phase 2b EVER-132-001 study of SG, which met its primary endpoint with a 38.8% overall response rate (ORR). This study included 80 people in China, and the results were consistent with those from the global Phase 3 ASCENT study, thus showing similar efficacy in the Chinese population.


© S&P Capital IQ 2022
All news about EVEREST MEDICINES LIMITED
04/07Everest Medicines to Form Vaccine JV With China Resources Pharmaceutical
MT
04/06Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent ..
CI
04/05Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent ..
PR
03/31Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan
CI
03/28Everest Medicines Narrows Loss as General, Administrative Expenses Fall in 2021
MT
03/28TRANSCRIPT : Everest Medicines Limited, 2021 Earnings Call, Mar 29, 2022
CI
03/28Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
PR
03/28Everest Medicines Limited Appoints Leah Liu as Joint Company Secretary
CI
03/21Calliditas Therapeutics AB - Updated regulatory plans for NEFECON in China
AQ
03/18Calliditas Therapeutics Says Partner Everest Medicines Plans to File Nefecon NDA in Chi..
MT
More news
Analyst Recommendations on EVEREST MEDICINES LIMITED
More recommendations
Financials
Sales 2022 193 M 28,6 M 28,6 M
Net income 2022 -1 095 M -162 M -162 M
Net cash 2022 873 M 129 M 129 M
P/E ratio 2022 -5,07x
Yield 2022 -
Capitalization 5 573 M 825 M 825 M
EV / Sales 2022 24,4x
EV / Sales 2023 2,97x
Nbr of Employees 405
Free-Float 100%
Chart EVEREST MEDICINES LIMITED
Duration : Period :
Everest Medicines Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVEREST MEDICINES LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 18,76 CNY
Average target price 34,67 CNY
Spread / Average Target 84,8%
EPS Revisions
Managers and Directors
Kerry Levan Blanchard Chief Executive Officer & Executive Director
Ian Ying Woo President, CFO & Executive Director
Wei Fu Executive Chairman
Xinhui Hu Chief Technology Officer
Jennifer Yang Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
EVEREST MEDICINES LIMITED-35.49%850
CSL LIMITED-6.06%91 946
SAMSUNG BIOLOGICS CO.,LTD.-11.85%44 385
BIOGEN INC.-18.43%28 662
WUXI BIOLOGICS (CAYMAN) INC.-42.79%28 457
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-26.31%22 129